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What Is the Standard
of Care for Patients With
Left Main Stenosis?*John D. Puskas, MD,yz Emmanuel Moss, MD, MSCy
Atlanta, Georgia
Invasive treatment strategies for coronary artery disease
(CAD) are highly scrutinized and constantly evolving.
Coronary artery bypass graft (CABG) surgery has long been
the gold standard for revascularization in patients with
complex CAD; however, advances in the safety and efﬁcacy
of percutaneous coronary intervention (PCI) have allowed
interventional cardiologists to challenge the status quo and
possibly expand the indications for coronary stenting. We
read with interest the meta-analysis by Athappan et al. (1)See page 1219reviewing the available published reports comparing
unprotected left main stenting (UPLMS) in the drug-
eluting stent (DES) era with CABG surgery. The analysis
included 3 randomized, controlled trials and 21 observa-
tional studies that were published between 2006 and 2012.
The authors selected appropriate primary (all-cause
mortality, target vessel revascularization, stroke, and
myocardial infarction) and secondary (major adverse cardiac
and cerebrovascular events) endpoints and performed
a thorough and statistically sound analysis. The result is
a valuable contribution to the published reports that
succinctly summarizes much of the available data comparing
CABG surgery with PCI for UPLMS and gives clinicians
a snapshot of the data, although the authors’ conclusions are
slightly overstated. The report also serves to highlight the
limited availability of high-quality short- and long-term
efﬁcacy and safety data on UPLMS. Unfortunately, as the
authors themselves point out, including a majority of
observational studies in this meta-analysis entails accepting*Editorials published in JACC: Cardiovascular Interventions reﬂect the views of the
authors and do not necessarily represent the views of JACC: Cardiovascular Interven-
tions or the American College of Cardiology.
From the yDivision of Cardiothoracic Surgery, Emory University School of
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to the contents of this paper to disclose.a certain degree of heterogeneity and uncontrollable bias
within the results.
In the most recent 2012 American College of Cardiology/
American Heart Association guidelines (2), CABG surgery
is the only Class I recommendation for revascularization to
improve survival in left main disease. This is based on many
studies performed over the past 2 decades that compared
CABG surgery with optimal medical therapy (3,4). PCI
has now been upgraded to a Class IIa indication only in
patients with very favorable anatomy (SYNTAX score <22,
ostial or trunk lesion) and who are at increased risk with
CABG surgery (Society of Thoracic Surgeons predicted
risk of mortality >5%). PCI is a class IIb indication if left
main anatomy is less favorable. These recommendations
are strongly driven by results from the SYNTAX (Synergy
between Percutaneous Coronary Intervention with Taxus
and Cardiac Surgery) trial, which randomized patients with
left main or multivessel coronary artery disease to undergo
CABG surgery or PCI (5). The SYNTAX trial, which was
underpowered to evaluate left main disease, was also the
only randomized trial included in this meta-analysis that
offered long-term (5-year) follow-up data. This is a funda-
mental ﬂaw of the present meta-analysis, and readers should
interpret these results with this important limitation in
mind. The short-term data, which come largely from non-
randomized, observational studies, suggest that UPLMS
is safe and effective early on. However, because the beneﬁts
of CABG surgery should become more evident over the
long term, a reasonable comparison with CABG surgery
must include longer follow-up of at least 3 to 5 years
or more. When the authors combined the randomized
SYNTAX data with nonrandomized, observational studies,
they found no difference in all-cause mortality, nonfatal
myocardial infarction, and cardiac mortality. In addition,
whereas CABG was found to be advantageous regarding
target vessel revascularization, stroke favored PCI, and there
was no difference in major adverse cardiac and cerebrovas-
cular events. These data are important and can certainly be
considered hypothesis generating; however, the effective
percutaneous treatment of left main disease is highly
nuanced and is dependent on the skills and experience of the
operator. Moreover, nonrandomized studies of PCI versus
CABG surgery are notoriously biased in numerous ways that
cannot be statistically adjusted with conﬁdence. For these
reasons, we believe that it is dangerous to draw concrete
conclusions from this very heterogeneous dataset.
When considering UPLMS, the anatomic location of the
lesion is of the utmost importance. The authors appropri-
ately focus part of the discussion on the signiﬁcance of
location of disease in left main lesions; however, this key
concept was not stressed in the paper’s conclusion. We
suspect, as the data suggest, that UPLMS is equal to or
better than CABG surgery in a select group of patients with
noncomplex ostial or mid-shaft left main lesions. Regarding
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1232distal left main lesions that may be heavily calciﬁed and
encroaching on the ostial left anterior descending and/or
circumﬂex arteries, we remain skeptical as to how long-term
results with PCI will compare with those with CABG
surgery. For diabetic patients, it is possible that even
noncomplex lesions are better treated with CABG surgery.
The FREEDOM (Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Management of
Multivessel Disease) trial, a large prospective, randomized
trial comparing PCI and CABG surgery among diabetic
patients with multivessel disease demonstrated that CABG
surgery was superior during 5 years of follow-up, with
respect to death, myocardial infarction, target vessel revas-
cularization, and major adverse cardiac events (6). Although
this trial excluded patients with left main disease, it clearly
demonstrated that diabetic patients can have a response to
revascularization therapy that differs from that of nondia-
betic patients. Further objective randomized data are
necessary to test the equivalence of outcomes after PCI for
simple versus more complex left main stenosis in both dia-
betic and nondiabetic patients. The need for a large,
randomized, controlled trial evaluating UPLMS is clear, and
enrollment has already begun in such a trial. The EXCEL
(Evaluation of XIENCE PRIME or XIENCE V vs.
Coronary Artery Bypass Surgery for Effectiveness of Left
Main Revascularization) trial will randomize 2,600 patients
to receive either PCI with a second-generation DES, or
CABG surgery (7). When 3-year follow-up is completed,
the results of this trial should provide some much-needed
answers regarding the optimal treatment strategy for this
group of patients with CAD.
The authors conclude that PCI with DES is comparable
to CABG surgery for left main disease patients with low
and intermediate SYNTAX scores. We would caution that
this statement may be premature and not fully substantiated.
In addition to the SYNTAX score, the decision to proceed
with UPLMS should also take into consideration the loca-
tion of the lesion and the experience of the operator. The
large series and randomized studies that have been published
originated in high-volume centers with very experienced
operators. It is not known whether similar results can
be achieved in smaller centers. Injudicious broad adoptionof UPLMS may put patients at unnecessary risk. As
mentioned earlier, the EXCEL trial should answer many
important questions about which patients may beneﬁt
from UPLMS, and we, along with the authors of this meta-
analysis, await the results of EXCEL with keen anticipation.
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